Search Results

0 results for 'Amgen Inc.'

You can use to get even better search results
Johnson v. Everyrealm Inc.
Publication Date: 2023-02-28
Practice Area: Dispute Resolution
Industry:
Court: U.S. District Court for the Southern District of New York, U.S. - SDNY
Judge: District Judge Paul A. Engelmayer
Attorneys:
For plaintiff:
For defendant:
Case number: 22 Civ. 6669

EFAA Renders Arbitration Clause Unenforceable in Viably Pleaded Sexual Harassment Dispute

February 23, 2023 | Law.com

Attorneys See Growth in Lawsuits Over Eye Disease Drug Tepezza

"This continues to grow into something that's larger than we first anticipated," said Ashlie Case Sletvold, of Peiffer Wolf Carr Kane Conway & Wise in Cleveland, who has filed two cases against Horizon Therapeutics, which makes Tepezza.
4 minute read
February 21, 2023 | The American Lawyer

Deal Watch: Davis Polk, Simpson, Jones Day and Latham Lead Debt Offering Charge

In the last week, Big Law handled a rash of debt offerings and SPAC combinations, as dealmakers focus on the work that is available.
9 minute read
January 24, 2023 | New York Law Journal

Supreme Court To Revisit the Patent Enablement Standard

The decision in 'Amgen v. Sanofi' has the potential to have a significant impact on inventors and patent drafters, and the breadth with which they may be able to claim their inventions.
7 minute read
Minaudo v. Sunrise at Sheepshead Bay
Publication Date: 2023-01-19
Practice Area: Civil Procedure | Covid-19
Industry:
Court: U.S. District Court for the Eastern District of New York, U.S. - EDNY
Judge: District Judge Eric Komitee
Attorneys:
For plaintiff:
For defendant:
Case number: 22-CV-2579

Death Action Remanded to State Court; Diversity Jurisdiction Threshold Amount Not Met

December 30, 2022 | National Law Journal

Supreme Court Will Again Be Focus of IP World in 2023

Despite having lost two of its strongest voices on IP in the last two years, the high court is wading into some 'meat and potatoes' IP issues such as pharma patents and copyright fair use.
10 minute read
Yale New Haven Hospital v. Becerra
Publication Date: 2022-12-27
Practice Area: Civil Procedure
Industry: Federal Government | Health Care
Court: U.S. Court of Appeals for the Second Circuit
Judge: Circuit Judge Richard J. Sullivan
Attorneys:
For plaintiff: For Plaintiff-Appellee-Cross-Appellant Yale New Haven Hospital: Patrick M. Noonan, Donahue, Durham & Noonan, P.C., Guilford, CT, on the brief, Robert L. Roth, Hooper Lundy & Bookman, PC, Washington, DC.
For defendant: For Defendant-Appellant-Cross-Appellee Xavier Becerra, Secretary of the U.S. Department of Health and Human Services: Jeffrey Bossert Clark, Acting Assistant Attorney General, Brian M. Boynton, Acting Assistant Attorney General, Alisa B. Klein, Appellate Staff Attorney, on the brief, Leif Overvold, Appellate Staff Attorney, Robert P. Charrow, General Counsel, Daniel J. Barry, Acting General Counsel, Janice L. Hoffman, Associate General Counsel, Susan Maxson Lyons, Deputy Associate General Counsel for Litigation, Jonathan C. Brumer, Staff Attorney, U.S. Department of Health and Human Services, Washington, DC, of counsel, Civil Division, U.S. Department of Justice, Washington, DC.
Case number: 20-2115

Statute Bars Any Challenge to HHS Secretary's Estimate of Hospital's Uncompensated Care

December 12, 2022 | Law.com

Who Got the Work?℠: Tesla Taps Wilmer Cutler Partner to Fend Off 'Self-Driving' Class Action + More

Welcome to "Who Got the Work?℠," a regular column that highlights the law firms and lawyers around the country who are being brought in to handle key cases and close major deals for their clients.
9 minute read
December 12, 2022 | The American Lawyer

Deal Watch: S&C and Cooley Advise on Largest Health Care Deal of the Year; Dealmakers Make 2023 Predictions

Amgen's buy of Horizon for $27.8 billion salvaged another slow week in M&A, but dealmakers expect activity to pick up in 2023.
8 minute read
December 12, 2022 | Daily Business Review

Dealmakers in Last-Minute $70B M&A Rush Before Holidays

Biotech giant Amgen is leading the flurry of transactions, saying it will buy Horizon Therapeutics for $28 billion to add drugs for rare disorders.
3 minute read

TRENDING STORIES

    Resources

    • Corporate Transparency Act Resource Kit

      Brought to you by Wolters Kluwer

      Download Now

    • Revenue, Profit, Cash: Managing Law Firms for Success

      Brought to you by Juris Ledger

      Download Now

    • Law Firm Operational Considerations for the Corporate Transparency Act

      Brought to you by Wolters Kluwer

      Download Now

    • The Ultimate Guide to Remote Legal Work

      Brought to you by Filevine

      Download Now